Home›CANCER

Lymphoma

Advanced diagnostic and therapeutic solutions for lymphatic system disorders, combining world class hematology expertise with the latest innovations in cellular therapy.

Cancer involves abnormal cells growing uncontrollably, invading nearby tissues, and spreading to other parts of the body through metastasis. 

We're Here to Help.
Get in Touch.

Send us all your questions or requests, and our expert team will assist you.

Doctors
GDPR

Overview and Definition of Lymphoma

The Lymphatic System and Immunological Architecture

The overview and definition of lymphoma provides essential insight into a group of blood cancers that begin in the lymphatic system. This page is designed for international patients and their families who are seeking clear, reliable information about lymphoma before making treatment decisions. According to the World Health Organization, lymphoma accounts for roughly 10% of all cancers worldwide, highlighting the importance of early awareness. In the following sections, you will find a detailed explanation of the disease, its causes, how it presents, diagnostic pathways, treatment modalities, and supportive care options available at Liv Hospital.

Our aim is to present an overview and definition that demystifies complex medical terminology while maintaining clinical accuracy. Whether you are a newly diagnosed patient, a caregiver, or a health‑conscious individual, this resource will help you understand the condition and explore the comprehensive services offered by a JCI‑accredited institution.

By reviewing this overview and definition, you will gain a clearer picture of what to expect throughout the care journey, from initial consultation to long‑term follow‑up.

Icon LIV Hospital

Understanding Lymphoma: Types and Classification

The Great Divide: Hodgkin versus Non-Hodgkin

Lymphoma is broadly categorized into two major families: Hodgkin lymphoma (HL) and non‑Hodgkin lymphoma (NHL). Each family encompasses several subtypes that differ in cellular origin, behavior, and response to therapy.

Hodgkin lymphoma is characterized by the presence of Reed‑Sternberg cells and typically follows a predictable pattern of spread. In contrast, non‑Hodgkin lymphoma includes a diverse group of over 60 subtypes, ranging from indolent (slow‑growing) to aggressive forms.

  • Classical Hodgkin lymphoma: Most common HL subtype, further divided into nodular sclerosis, mixed cellularity, lymphocyte‑rich, and lymphocyte‑depleted.
  • Diffuse large B‑cell lymphoma (DLBCL): The most frequent aggressive NHL, often requiring intensive chemotherapy.
  • Follicular lymphoma: An indolent NHL that may remain stable for years before needing treatment.
  • Burkitt lymphoma: Highly aggressive but highly responsive to short‑duration chemotherapy.

Understanding these classifications is crucial because treatment strategies and prognoses vary significantly between subtypes. At Liv Hospital, a multidisciplinary team conducts precise histopathological and molecular analyses to accurately identify the specific lymphoma type, ensuring personalized care.

Icon 1 LIV Hospital

Causes and Risk Factors

Cellular Origins: B Cell versus T Cell Malignancies

While the exact cause of lymphoma remains uncertain, research has identified several factors that increase susceptibility. Recognizing these risk elements can aid in early detection and preventive counseling.

  • Genetic predisposition: Certain inherited gene mutations, such as those affecting the immune system, elevate risk.
  • Immunodeficiency: Conditions like HIV/AIDS or immunosuppressive therapy after organ transplantation are linked to higher lymphoma incidence.
  • Chronic infections: Epstein‑Barr virus (EBV), Helicobacter pylori, and hepatitis C have been associated with specific lymphoma subtypes.
  • Environmental exposures: Prolonged contact with chemicals like benzene, pesticides, or certain solvents may contribute.
  • Age and gender: Hodgkin lymphoma is more common in young adults, while NHL incidence rises with age and is slightly higher in men.

It is important to note that having one or more risk factors does not guarantee development of lymphoma, just as many patients are diagnosed without identifiable risk factors. Lifestyle modifications, such as smoking cessation and maintaining a healthy immune system, can mitigate some modifiable risks.

Symptoms and Early Detection

Lymphoma often presents with subtle, nonspecific symptoms that can be mistaken for common infections. Early recognition of warning signs facilitates prompt evaluation and improves outcomes.

  • Enlarged, painless lymph nodes in the neck, armpits, or groin.
  • Unexplained fever and night sweats (so‑called “B symptoms”).
  • Unintentional weight loss of more than 10% of body weight over six months.
  • Fatigue that does not improve with rest.
  • Itching (pruritus) or skin rashes.
  • Chest pain, shortness of breath, or coughing if mediastinal nodes are involved.

Because these manifestations overlap with many benign conditions, a thorough clinical evaluation is essential. At Liv Hospital, international patients benefit from a streamlined appointment system that includes virtual pre‑consultations, enabling early triage based on symptom profiles.

Symptoms and Causes

Diagnostic Procedures and Staging

The Global Burden and Epidemiology

Accurate diagnosis relies on a combination of imaging, laboratory, and tissue‑based studies. Staging determines the extent of disease spread and guides therapeutic planning.

Procedure

Purpose

Key Findings

 

Excisional Lymph Node Biopsy

Obtain sufficient tissue for histology

Identification of Reed‑Sternberg cells or specific lymphoma subtypes

Positron Emission Tomography (PET) Scan

Assess metabolic activity and disease distribution

Standardized Uptake Value (SUV) helps gauge aggressiveness

Computed Tomography (CT) Scan

Visualize anatomical involvement

Size and location of lymphadenopathy

Bone Marrow Aspiration/Biopsy

Detect marrow infiltration

Presence of lymphoma cells in hematopoietic tissue

Flow Cytometry & Molecular Testing

Characterize cell surface markers and genetic abnormalities

Immunophenotype and chromosomal translocations (e.g., t(14;18))

Staging follows the Ann Arbor system, ranging from Stage I (localized) to Stage IV (disseminated). The comprehensive diagnostic pathway at Liv Hospital integrates state‑of‑the‑art imaging with expert pathology review, ensuring each patient receives an accurate stage classification.

Diagnosis and Staging

Treatment Options and Emerging Therapies

Therapeutic strategies for lymphoma are tailored to subtype, stage, patient age, and overall health. Conventional modalities remain the cornerstone of care, while innovative treatments are expanding the therapeutic arsenal.

  • Chemotherapy: Regimens such as ABVD for Hodgkin lymphoma and R‑CHOP for diffuse large B‑cell lymphoma are widely used.
  • Radiation Therapy: Often combined with chemotherapy for localized disease to improve local control.
  • Immunotherapy: Monoclonal antibodies (e.g., rituximab) target CD20‑positive B‑cell lymphomas, enhancing response rates.
  • Targeted Therapy: Agents like ibrutinib inhibit specific signaling pathways in mantle cell and chronic lymphocytic leukemia.
  • Stem Cell Transplantation: Autologous or allogeneic transplants offer curative potential for refractory or relapsed cases.
  • CAR‑T Cell Therapy: Genetically engineered T‑cells directed against CD19 have shown remarkable efficacy in certain relapsed NHLs.

Liv Hospital’s oncology department collaborates with international research networks, providing patients access to clinical trials investigating novel checkpoint inhibitors, bispecific antibodies, and personalized vaccine approaches. A multidisciplinary tumor board reviews each case to select the optimal combination of standard and experimental therapies.

Treatment Details

Living with Lymphoma: Support and Follow‑Up Care

Beyond medical treatment, comprehensive care addresses psychosocial, nutritional, and rehabilitative needs. Survivorship programs are essential for maintaining quality of life.

  • Psychological Counseling: Licensed therapists offer coping strategies and stress management.
  • Nutrition Services: Dietitians create individualized plans to support immune function and manage treatment side effects.
  • Physical Rehabilitation: Exercise physiologists develop safe activity regimens to combat fatigue and preserve strength.
  • Patient Navigation: Dedicated coordinators assist with travel arrangements, interpreter services, and accommodation for international visitors.
  • Long‑Term Surveillance: Regular imaging and blood tests monitor for recurrence and late effects of therapy.

The comprehensive overview and definition presented here underscores that lymphoma is a manageable disease when approached with a coordinated, patient‑centered strategy. Liv Hospital’s 360‑degree international patient services ensure that every aspect of the journey—from diagnosis to survivorship—is supported with expertise and compassion.

Maintenance and Care

Why Choose Liv Hospital?

Liv Hospital is a JCI‑accredited private medical center in Istanbul that specializes in delivering world‑class oncology care to patients from around the globe. Our multidisciplinary team combines advanced diagnostic technology, cutting‑edge treatment protocols, and personalized support services, including visa assistance, airport transfers, and multilingual interpreters. By choosing Liv Hospital, international patients gain access to a seamless, high‑quality experience that prioritizes both clinical excellence and comfort.

Ready to take the next step in your lymphoma care journey? Contact Liv Hospital today to schedule a personalized consultation and discover how our expert team can guide you toward recovery.

Get an Online Consultation with
Certified Doctors

Clinics/branches
GDPR

Related Doctors

Assoc. Prof. MD. Evrim Duman Liv Hospital Ulus Assoc. Prof. MD. Evrim Duman Radiation Oncology Asst. Prof. MD. Meltem Topalgökçeli Selam Liv Hospital Ulus Asst. Prof. MD. Meltem Topalgökçeli Selam Medical Oncology Prof. MD. Duygu Derin Liv Hospital Ulus Prof. MD. Duygu Derin Medical Oncology Prof. MD. Emre Merdan Fayda Liv Hospital Ulus Prof. MD. Emre Merdan Fayda Radiation Oncology Prof. MD. Meral Günaldı Liv Hospital Ulus Prof. MD. Meral Günaldı Medical Oncology Assoc. Prof. MD. Murat Ayhan Liv Hospital Vadistanbul Assoc. Prof. MD. Murat Ayhan Medical Oncology Prof. MD. Itır Şirinoğlu Demiriz Liv Hospital Vadistanbul Prof. MD. Itır Şirinoğlu Demiriz Hematology Prof. MD. Tülin Tıraje Celkan Liv Hospital Vadistanbul Prof. MD. Tülin Tıraje Celkan Pediatric Hematology and Oncology Assoc. Prof. MD. Erkan Kayıkçıoğlu Liv Hospital Bahçeşehir Assoc. Prof. MD. Erkan Kayıkçıoğlu Medical Oncology Assoc. Prof. MD. Mine Dağgez Liv Hospital Bahçeşehir Assoc. Prof. MD. Mine Dağgez Gynecological Oncology Assoc. Prof. MD. Ozan Balakan Liv Hospital Bahçeşehir Assoc. Prof. MD. Ozan Balakan Medical Oncology MD. Taylan Bükülmez Liv Hospital Bahçeşehir MD. Taylan Bükülmez Radiation Oncology Op. MD. Alp Koray Kinter Liv Hospital Bahçeşehir Op. MD. Alp Koray Kinter Gynecological Oncology Prof. MD. Nuri Faruk Aykan Liv Hospital Bahçeşehir Prof. MD. Nuri Faruk Aykan Medical Oncology Prof. MD. Yasemin Altuner Torun Liv Hospital Bahçeşehir Prof. MD. Yasemin Altuner Torun Pediatric Hematology and Oncology Spec. MD. Vildan Kayku Liv Hospital Bahçeşehir Spec. MD. Vildan Kayku Medical Oncology Spec. MD. Özlem Doğan Liv Hospital Bahçeşehir Spec. MD. Özlem Doğan Medical Oncology Assoc. Prof. MD. Emir Çelik Liv Hospital Topkapı Assoc. Prof. MD. Emir Çelik Medical Oncology Assoc. Prof. MD. Muhammed Mustafa Atcı Liv Hospital Topkapı Assoc. Prof. MD. Muhammed Mustafa Atcı Medical Oncology Prof. MD. İrfan Çiçin Liv Hospital Topkapı Prof. MD. İrfan Çiçin Medical Oncology Assoc. Prof. MD. Ramazan Öcal Liv Hospital Ankara Assoc. Prof. MD. Ramazan Öcal Hematology Assoc. Prof. MD. Nazlı Topfedaisi Özkan Liv Hospital Ankara Assoc. Prof. MD. Nazlı Topfedaisi Özkan Gynecological Oncology Prof. MD. Fikret Arpacı Liv Hospital Ankara Prof. MD. Fikret Arpacı Medical Oncology Prof. MD. Gökhan Erdem Liv Hospital Ankara Prof. MD. Gökhan Erdem Medical Oncology Prof. MD. Meral Beksaç Liv Hospital Ankara Prof. MD. Meral Beksaç Hematology Prof. MD. Oral Nevruz Liv Hospital Ankara Prof. MD. Oral Nevruz Hematology Prof. MD. Saadettin Kılıçkap Liv Hospital Ankara Prof. MD. Saadettin Kılıçkap Medical Oncology Prof. MD. Sadık Muallaoğlu Liv Hospital Ankara Prof. MD. Sadık Muallaoğlu Medical Oncology Spec. MD. Ender Kalacı Liv Hospital Ankara Spec. MD. Ender Kalacı Medical Oncology Assoc. Prof. MD. Fadime Ersoy Dursun Liv Hospital Gaziantep Assoc. Prof. MD. Fadime Ersoy Dursun Hematology Prof. MD. Fatih Teker Liv Hospital Gaziantep Prof. MD. Fatih Teker Medical Oncology Spec. MD. ELXAN MEMMEDOV Liv Bona Dea Hospital Bakü Spec. MD. ELXAN MEMMEDOV Medical Oncology Spec. MD. Ceyda Aslan Spec. MD. Ceyda Aslan Hematology Spec. MD. Elkhan Mammadov Spec. MD. Elkhan Mammadov Medical Oncology Spec. MD. Elmir İsrafilov Spec. MD. Elmir İsrafilov Hematology Spec. MD. Minure Abışova Eliyeva Spec. MD. Minure Abışova Eliyeva Hematology Spec. MD. Natavan Azizova Spec. MD. Natavan Azizova Medical Oncology Prof. MD. Mehmet Hilmi Doğu Liv Hospital Ulus + Liv Hospital Bahçeşehir Prof. MD. Mehmet Hilmi Doğu Hematology

30 Years of
Excellence

Trusted Worldwide

With patients from across the globe, we bring over three decades of medical

Group 346 LIV Hospital

Reviews from 9,651

4,9

Worth a look

Related Videos
Departments
Our Doctors
News

Was this article helpful?

Was this article helpful?

I didn't like it
I LIKE

We're Here to Help.
Get in Touch.

Send us all your questions or requests, and our expert team will assist you.

Doctors
GDPR

FREQUENTLY ASKED QUESTIONS

What are the main types of lymphoma?

Hodgkin lymphoma is identified by Reed‑Sternberg cells and usually spreads in a predictable pattern. Non‑Hodgkin lymphoma comprises over 60 subtypes, ranging from indolent forms like follicular lymphoma to aggressive ones such as diffuse large B‑cell lymphoma (DLBCL) and Burkitt lymphoma. The specific subtype influences treatment choices and prognosis, so precise pathological and molecular testing is essential.

People with inherited immune‑system gene mutations, HIV/AIDS, or who receive immunosuppressive therapy after organ transplantation have higher lymphoma risk. Chronic infections like Epstein‑Barr virus, Helicobacter pylori, and hepatitis C are linked to specific subtypes. Long‑term exposure to benzene, pesticides, or solvents may also contribute. While these factors raise susceptibility, many patients develop lymphoma without any identifiable risk.

Lymphoma often presents with subtle, nonspecific symptoms that mimic infections. The classic “B symptoms” include fever, night sweats, and weight loss of more than 10% body weight. Additional signs are enlarged painless nodes in the neck, armpits, or groin, chronic fatigue, pruritus, and respiratory symptoms if mediastinal nodes are involved. Because these signs overlap with benign conditions, any combination persisting for weeks should trigger a thorough clinical work‑up.

Chemotherapy regimens like ABVD for Hodgkin lymphoma and R‑CHOP for DLBCL remain first‑line. Radiation is added for localized disease. Immunotherapy with monoclonal antibodies (e.g., rituximab) targets CD20‑positive B‑cell lymphomas. Targeted agents such as ibrutinib inhibit specific signaling pathways in certain subtypes. Autologous or allogeneic stem‑cell transplantation offers curative potential for refractory cases. CAR‑T cell therapy, which engineers T‑cells to attack CD19, shows high response rates in relapsed NHL. Clinical trials at Liv Hospital provide access to novel checkpoint inhibitors and bispecific antibodies.

Chimeric Antigen Receptor T‑cell (CAR‑T) therapy involves extracting a patient’s T‑cells, genetically engineering them to express a receptor that binds CD19, a protein on most B‑cell lymphomas, and reinfusing them. The engineered cells proliferate and destroy cancer cells. It is typically reserved for patients with relapsed or refractory diffuse large B‑cell lymphoma, transformed follicular lymphoma, or other CD19‑positive NHLs after standard therapies have failed. Side effects can include cytokine release syndrome and neurotoxicity, which are managed in specialized centers like Liv Hospital.

Spine Hospital of Louisiana
Need Help? Chat with our medical team

Let's Talk on WhatsApp

📌

Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.

or call us at +90 530 174 28 17
liv-hospital-seeklogo
+90 530 174 28 17
Facebook-f X-twitter Instagram Youtube Linkedin-in Tiktok

How helpful was it?

helpful
GDPR
helpful
GDPR
helpful
GDPR
Contact Us
Contact Us
Medical Second Opinion